MediaMedic

Advancing Prostate Cancer Diagnosis: Professor Declan Murphy Presents Results from the TRANSLATE Trial Comparing TP vs TRUS Biopsy

By Peng Longmei 2025.04.15

At the highly anticipated Game Changer Session at EAU25, Professor Declan Murphy (Peter MacCallum Cancer Centre, Melbourne) delivered an impactful presentation on the results of the TRANSLATE trial, a multicentre,…

EBMT 2025 | Post-Transplant Outcomes in AML with Haploidentical Donors

By Mourabit Halima 2025.04.15

At the 51st Annual Meeting of EBMT, Dr. Eduardo Rodríguez-Arbolí presented important long-term data from an ALWP-EBMT study focusing on patients with acute myeloid leukemia (AML) who underwent haploidentical HSCT…

EAU25 | Final Survival Results from SPCG-13 Trial: Surveillance vs. Docetaxel After Radiotherapy in High-Risk Prostate Cancer

By Peter W. PENG 2025.04.15

In a Game Changer Session at EAU25, Prof. Kellokumpu-Lehtinen Pirkko-Liisa presented the 10-year follow-up from the Scandinavian Prostate Cancer Study Group-13 trial (SPCG-13), exploring adjuvant docetaxel versus surveillance following curative…

Can a short video ease the mind of a worried parent?

By Mourabit Halima 2025.04.15

At EAU25, Dr. Mehmet Cetin from Marmara University School of Medicine (Istanbul) presented a prospective randomized controlled study evaluating the impact of video-based informed consent on the anxiety levels of…

APASL China Voice | Dr. Rong Fan: The Application of Cell-Free DNA Testing in Early Hepatocellular Carcinoma Surveillance

By Lisa Cui 2025.04.14

Editor’s Note: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. The overall prognosis for HCC remains poor, with a five-year…

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Professor Bingcheng Liu: Exploring B-ALL from Personalized Immunity to Precision Immunotherapy | 2026 China-France Scientific Symposium on Hematology and Immunology

CSCO 2026 Global Perspective | Professor Franco Cavalli: From Teaching to Learning—Witnessing China’s Transformation in Oncology and Exploring Lymphoma Frontiers and ICML 2027 Highlights

Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies

CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Advancing Prostate Cancer Diagnosis: Professor Declan Murphy Presents Results from the TRANSLATE Trial Comparing TP vs TRUS Biopsy

EBMT 2025 | Post-Transplant Outcomes in AML with Haploidentical Donors

EAU25 | Final Survival Results from SPCG-13 Trial: Surveillance vs. Docetaxel After Radiotherapy in High-Risk Prostate Cancer

Can a short video ease the mind of a worried parent?

APASL China Voice | Dr. Rong Fan: The Application of Cell-Free DNA Testing in Early Hepatocellular Carcinoma Surveillance

APASL 2025 | Dr. Yinying Lu’s Team Unlocks New Multidimensional Strategies in Liver Cancer Treatment

Allogeneic Transplant Outcomes in Severe Aplastic Anemia: What Role Does Donor Type Play?

Relapsed B-ALL Post CAR-T Therapy: Addressing a Growing Clinical Challenge | EBMT 2025

Late Effects After Auto-HSCT in Autoimmune Diseases: A Call for Long-Term Monitoring

Clonal Hematopoiesis in Pediatric HCT Survivors: New Insights from Dr. Konradin Müskens at EBMT 2025

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.